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Introduction 
Chronic kidney disease (CKD) is a 
complex condition which impacts on an 
individual’s health-related quality of life 
(HRQoL) and ability to perform everyday 
activities. Fatigue is also a common 
symptom experienced by people with 
CKD. Little however is known about the 
influence of anaemia and whether fatigue 
contributes to HRQoL and activity levels 
over time. 
 
•45% of people with CKD in stages 4 and 
5 develop anaemia (Gandra et al. 2010) 
 
Anaemia is associated with decreased 
energy, tiredness, shortness of breath, 
weakness 
 
ESA (erythropoietin stimulating agent) is 
prescribed to increase haemoglobin 
levels and reduce these symptoms 
 
Fatigue is experienced by 70-97% of 
people with CKD (Murtagh et al., 2007) 
 
CKD patients prescribed an ESA for 
anaemia report higher fatigue levels 
(Bonner et al., 2008) 
 
People with CKD have a reduced 
capacity to engage in activities of daily 
living including exercise (Bonner et al., 
2009) 
 
Survival is longer in people with a better 
HRQoL & better health status, and less 
morbidity is associated with higher 
HRQoL (Untas et a., 2011) 
 
Aim 
This study sought to examine HRQoL, 
activity and fatigue levels of people with 
anaemia secondary to CKD over a 12 
month period following the introduction of 
erythropoietin stimulating agent (ESA). 
Discussion 
A consequence of impaired renal function is 
development of severe anaemia which affects 
normal physiological function, causes  
increased tiredness and reduces the ability to 
undertake daily activities including exercise. 
 
We found that people with CKD prior to 
commencing an ESA have lower HRQoL when 
compared to healthy people, particularly 
apparent in SF-36 physical components (See 
Table 1). Levels of physical functioning and 
general health, as well as being able to 
undertake fewer physical roles contributed to 
lower HRQoL. Our sample had lower levels of 
vitality and experienced more difficulty with 
social functioning than healthy people, a 
finding consistent with Perlman et al. (2005). 
 
When ESA treatment was commenced, there 
are some improvements in HRQoL, 
breathlessness (dyspnoea) and levels of 
fatigue over 12 months though their ability to 
undertake more activities does not change 
(Table 2). Improvements were seen for mental 
health components of the SF-36 (vitality and 
emotional well-being), a finding consistent with 
the literature (Gandra et al., 2010; Hamilton & 
Hawley, 2006). Our findings are also 
consistent with Johansen et al. (2011) that 
level of fatigue in dialysis patients is reduced 
as haemoglobin levels are corrected. 
 
Although ESA has improved the potential for 
higher activity levels, there has not been a 
corresponding increase in activity levels as 
shown at 3, 6 and 12 months. 
 
Conclusion 
There is a need for increased assessment by 
health-care teams to identify and monitor 
changes in HRQoL, fatigue and activity levels 
in people with CKD 
Early detection of a person’s inability to 
engage in normal daily activities due to 
increasing levels of fatigue is necessary to 
allow timely interdisciplinary interventions 
which use behavioural and problem-solving 
techniques to optimize HRQoL and 
independent activity. 
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Results 
Table 1: SF-36 means, sd and repeated measures ANOVA 
scores 
 
Table 2: HAP, Dyspnoea and fatigue mean and sd scores for 
repeated measures ANOVA 
Method 
Participants 
28 people with CKD  
Aged 31-84 years (Mean=64) 
 
Materials 
HRQoL measured by SF-36 (Ware, 2011) 
Daily physical activity measured by Human 
Activity Profile (HAP)  
Fatigue measured by Fatigue Severity 
Scale (FSS) 
 
Data was collected at baseline (prior to 
commencing ESA, 3 months, 6 months and 
12 months 
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SF-36 Scales 
 
 
 
Baseline 
CKD 
Sample 
 
3 months 
 
 
 
6 months 
 
 
 
12 months 
Normative 
sample 
 
 
 
F 
 
 
 
p 
Physical Health 
Physical functioning 
(PF) 
42.7 
(28.1) 
47.39 
(31.1) 
54.75 
(27.6) 
25.45  
(13.7) 
84.2  
(23.3) 
3.96 ns 
Role physical (RP) 41.17 
(40.4) 
10.85 
(4.4) 
80.76 
(32.5) 
63.63  
(34.2) 
80.9 
(34.0) 
12.29 P<.05 
Bodily pain (BP) 70.1 
(33.2) 
74.43 
(26.8) 
50.75 
(24.1) 
48 
(20.8) 
75.2 
(23.7) 
.084 ns 
General health (GH) 41.66 
(18.6) 
44.3 
(21.45) 
15.19 
(4.5) 
14.12 
(4.45) 
71.9 
(20.3) 
.64 ns 
Physical health 
summary 
56.6 
(20.5) 
44.58 
(15.8) 
72.13 
(21.8) 
56.38 
(14.1) 
50 
(10.0) 
- - 
Mental Health 
Vitality (VT) 38.04 
(20.6) 
46.42 
(24.5) 
52.61 
(24.0) 
50.0 
(22.1) 
60.9 
(20.9) 
3.93 P<.05 
Social functioning 
(SF) 
61.05 
(32.4) 
69.04 
(28.9) 
78.12 
(31.4) 
75.73 
(26.3) 
83.3 
(22.7) 
1.96 ns 
Role emotional (RE) 63.88 
(44.9) 
85.0 
(29.6) 
94.11 
(13.1) 
86.66 
(27.6) 
81.3 
(33.0) 
.718 ns 
Mental health (MH) 71.52 
(15.2) 
74.95 
(15.6) 
78.85(21.1) 82.13(12.9) 74.7 
(18.1) 
3.62 P<.05 
Mental health 
summary 
60.18 
(21.8) 
71.57 
(17.8) 
80.46 
(13.9) 
73.48 
(15.7) 
50 
(10.0) 
- - 
Baseline 
M (sd) 
3 months 
M (sd) 
6 months 
M (sd) 
12 
months 
M (sd) 
Normative 
 sample 
F p 
HAP scores 
Total activity 43.4 
(17.7) 
47.95 
(20.1) 
47.61 
(23.6) 
48.22 
(23.23) 
83.0 2.14 ns 
Self-care 7.31 
(1.12) 
7.04 
 (1.77) 
7.52 
(0.98) 
7.6 
 (0.77) 
7.8 1.30 ns 
Personal/ 
Household work 
14.19 
(6.7) 
15.48 
 (7.2) 
17.19 
(6.03) 
17.27 
 (4.52) 
24.1 2.99 ns, 
p=.07 
Entertainment/ 
Social 
7.88 
(2.87) 
8.04 
 (2.53) 
8.85 
(2.61) 
9.05 
 (2.53) 
13.6 2.47 ns 
Independent 
exercise 
6.35 
(5.26) 
7.3 
 (5.04) 
7.9  
(6.17) 
8.10 
(6.34) 
22.2 1.02 ns 
Dyspnoea scores 
Dyspnoea 14.28 
(7.61) 
13.12 
(8.34) 
11.59 
(7.74) 
11.10 
 (7.90) 
- 2.14 ns 
FSS scores 
Fatigue 47.69 
(13.18) 
47.61 
(12.8) 
38.7 
(17.18) 
42.35 
(13.19) 
- 3.78 P<.05 
